Alexandra Gerlach, Content Producer

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Phase 3 PATCH trial data show estrogen patches reduce hot flashes but raise gynecomastia risk.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

A pharmacist's guide to the most common cancer myths circulating online.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.

A long-term study reveals that high-fat cheese consumption may lower dementia risk, challenging traditional views on dietary fat and brain health.

Prolonged exposure to specific air pollution components significantly increases depression risk in older adults, highlighting the need for targeted regulations.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

Measles cases surge in the US, prompting quarantine measures in South Carolina schools and raising urgent vaccination concerns amid declining rates.